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Abstract
Background: In vitro and observational epidemiological studies suggest that vitamin D
may play a role in cancer prevention. However, the relationship between vitamin D and
ovarian cancer is uncertain, with observational studies generating conflicting findings. A
potential limitation of observational studies is inadequate control of confounding. To
overcome this problem, we used Mendelian randomization (MR) to evaluate the associ-
ation between single nucleotide polymorphisms (SNPs) associated with circulating 25-
hydroxyvitamin D [25(OH)D] concentration and risk of ovarian cancer.
Methods: We employed SNPs with well-established associations with 25(OH)D concen-
tration as instrumental variables for MR: rs7944926 (DHCR7), rs12794714 (CYP2R1) and
rs2282679 (GC). We included 31 719 women of European ancestry (10 065 cases, 21 654
controls) from the Ovarian Cancer Association Consortium, who were genotyped using
customized Illumina Infinium iSelect (iCOGS) arrays. A two-sample (summary data) MR
approach was used and analyses were performed separately for all ovarian cancer (10
065 cases) and for high-grade serous ovarian cancer (4121 cases).
Results: The odds ratio for epithelial ovarian cancer risk (10 065 cases) estimated by com-
bining the individual SNP associations using inverse variance weighting was 1.27 (95%
confidence interval: 1.06 to 1.51) per 20 nmol/L decrease in 25(OH)D concentration. The
estimated odds ratio for high-grade serous epithelial ovarian cancer (4121 cases) was
1.54 (1.19, 2.01).
Conclusions: Genetically lowered 25-hydroxyvitamin D concentrations were associated
with higher ovarian cancer susceptibility in Europeans. These findings suggest that
increasing plasma vitamin D levels may reduce risk of ovarian cancer.
Key words:
Introduction
Ovarian cancer is one of the most fatal cancers among
women.1 Survival following diagnosis is poor (less than
50% at 5 years post-diagnosis) with a mortality rate of
152 000 per year worldwide.2,3 The most common histolo-
gical subtype is serous carcinoma (further classified into
high-grade serous and low-grade serous); other subtypes
include mucinous, clear cell and endometrioid carcin-
omas.4 Higher parity and oral contraceptive use reduce
risk whereas established risk factors include a history of
endometriosis, obesity and family history of ovarian or
breast cancer.5 Several recent studies have examined
whether or not serum 25-hydroxyvitamin D [25(OH)D]
concentrations are associated with ovarian cancer risk or
mortality.6–12
Vitamin D is produced in the skin when 7-dehydrochol-
esterol is exposed to Ultraviolet B. It is transported to the
liver, where it is hydroxylated to become 25(OH)D. It then
undergoes a second hydroxylation step, primarily in the
liver, to become the active form, 1,25-dihydroxyvitamin
D (calcitriol). Whereas 25(OH)D is relatively inactive, it
has a long half-life and its production is loosely regulated,
Key Messages
• Previous observational studies have reported conflicting findings on the association between serum 25(OH)D concen-
tration and ovarian cancer.
• Results from this study suggest that lower 25(OH)D concentration associates with higher susceptibility to ovarian
cancer.
• Among different ovarian cancer subtypes, the magnitude of association was the highest for high-grade serous ovar-
ian cancer.
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making it a useful indicator of vitamin D status. In vitro
and animal studies suggest that calcitriol has a variety of
anti-cancer effects, including the prevention of cell disjunc-
tion,13–16 preventing overgrowth and exerting multiple
anti-proliferative and anti-inflammatory effects.17
The association between vitamin D and ovarian cancer
is controversial. Most recent observational studies found
no strong evidence for an association between circulating
25(OH)D and risk for this cancer.7,8,10,18–20 One limita-
tion of these studies is that their findings may only be gen-
eralized for specific populations because of the latitudes in
which they were conducted. Furthermore, the variety of
different 25(OH)D measurement techniques as well as the
different subtype distribution of ovarian cancers used in
the various studies might have also affected the results.8
More fundamentally, a limitation of observational studies
is that confounding and reverse causation can make it diffi-
cult to interpret the results. For example, affected individ-
uals may have altered vitamin D levels due to their disease
status. Randomized clinical trials (RCT) are an attractive
alternative to observational studies, as these remove biases
from confounding and reverse causation. However, RCTs
are costly and logistically cumbersome, and there are no
published RCTs assessing the relationship between
25(OH)D levels and risk of epithelial ovarian cancer.
Mendelian randomization (MR) is an approach for
evaluating associations of an exposure with a disease.21,22
This technique utilizes the fact that allelic variants are as-
signed at random during meiosis, making them potentially
robust and unbiased (free from confounding effects) instru-
ments to gauge the effect of an exposure (e.g. low vitamin
D) on a trait (e.g. cancer).22 An instrumental variable
(SNP) used in a MR study also has to satisfy the following
assumptions21,22: (i) the instrumental variable is associated
with the exposure of interest, (ii) the instrumental variable
is independent of confounding factors that might confound
the association of the exposure with the outcome and (iii)
the instrumental variable is only associated with the out-
come through the exposure (Figure 1). Two key
determinants of the power of an MR study are the variance
in the modifiable exposure explained by the genetic vari-
ants (SNPs) and the sample size of the study associating the
relevant SNPs with the trait of interest. To date, SNPs
associated with vitamin D level explain only a very small
proportion (approximately 1–4%) of the trait variance.
Therefore, for MR to be informative for vitamin D concen-
trations, large sample sizes are needed. Here we use large-
scale data from the Ovarian Cancer Association
Consortium (OCAC) in an MR framework to assess
whether or not SNPs associated with 25(OH)D concentra-
tion are related to risk of ovarian cancer.
Methods
Data sources
Individual-level genetic data from the OCAC were used in
this study. Participants from 43 studies from around the
world were genotyped using the Illumina Infinium iSelect
(iCOGS) array.23 Quality control was as per previous
work, with related individuals and ancestry outliers
removed.4 We excluded 13 studies of individuals of non-
European ancestry4; the remaining studies that contributed
to our analysis are listed in Supplementary Table 4 (avail-
able as Supplementary data at IJE online). For examin-
ation of all histotypes of ovarian cancer combined, we had
10 065 cases and 21 654 controls for analysis. The distri-
bution of histological subtypes is shown in Table 1. For
high-grade serous ovarian cancer, 4121 cases were avail-
able. We also performed MR analysis on the other sub-
types individually, although sample sizes were much
smaller than for high-grade serous cancer.
SNP selection criteria
Several SNPs have been observed in association with
25(OH)D concentrations: rs6013897 in the Cytochrome
P450, family 24, subfamily A, polypeptide 1 (CYP24A1)
gene; rs2282679 and rs7041 in the Group-Specific
Figure 1. Schematic of the Mendelian randomization framework in our study using vitamin D SNPs as instrumental variables.
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Component (GC) gene; rs12800438 and rs7944926 near
the 7-Dehydrocholesterol Reductase (DHCR7) gene; and
rs10741657 and rs12794714 in the Cytochrome P450,
family 2, subfamily R, polypeptide 1 (CYP2R1) gene.24–30
The iCOGs array directly genotyped rs12794714 and
rs2282679; rs7944926 was the best imputed DHCR7
SNPs (imputation quality score of 0.92) described by previ-
ous study.31 We were unable to include rs6013897 in
CYP24A1, as there were no SNPs in adequate linkage dis-
equilibrium (>0.3) genotyped on our arrays. These SNPs
are potential instrumental variables with respect to
25(OH)D concentrations. To ensure that these SNPs in-
struments can be applied to the MR via summary statistics
approach, we first required accurate 25(OH)D association
estimates for each of the SNP—the most accurate estimates
available were those from Afzal et al.31 for the SNPs
within/near DHCR7 and CYP2R1, whereas the estimates
for the GC SNP is only available in Mokry et al.26 [the ef-
fect of the GC SNP on 25(OH)D was only estimated based
on 2347 individuals26 whereas the estimates for DHCR7
and CYP2R1 were derived based on 30 792 individuals31].
We then examined their associations with various potential
confounders using publicly available GWAS datasets (the
complete list of potential confounders that were investi-
gated is available in Supplementary Table 1, available as
Supplementary data at IJE online).
Statistical analyses
MR operates by comparing the estimated magnitude of the
association of the SNPs on the modifiable risk factor
[25(OH)D concentration] with the magnitude of the asso-
ciation of the SNP on the outcome of interest (ovarian can-
cer). Estimates of the association of the relevant SNPs with
ovarian cancer status were derived using logistic regres-
sions using SNPTEST.32 We adjusted for intra-ethnic (i.e.
within Europeans) population differences by incorporating
the first six principal components and indicators for study
number as covariates in the SNP-outcome regressions. To
check for evidence of residual population stratification, we
computed the genomic control lambda value from 195 183
directly genotyped autosomal SNPs genome-wide.
Additional confounding variables such as time spent out-
doors, socio-economic status and body mass index (BMI)
were not adjusted in our model, as this information was
not available on all individuals in our dataset. Instead,
samples with available confounder data (n< 26 000) were
retained for subsequent sensitivity analysis (see the
‘Discussion’ section).
In the absence of information on 25(OH)D concentra-
tion levels in the OCAC dataset, we applied a two-sample
approach that uses only summary data to assess indirect
associations33 where estimates for the SNP-outcome asso-
ciations are from a different sample than the SNP-exposure
associations. Here, we obtain 25(OH)D association esti-
mates from GWAS summary statistics for SNP instruments
that passed the selection criteria mentioned above.
Combining these magnitudes of association, the associ-
ation of 25(OH)D concentration levels on ovarian cancer,
the weighted estimate can be computed using the Wald-
type ratio estimator.21 The weighted model that was used
to obtain the instrumental variable estimates are shown in
the Supplementary section (available as Supplementary
data at IJE online). Analyses were performed for all epithe-
lial ovarian cancers irrespective of histological subtype and
separately for high-grade serous epithelial ovarian cancer.
To be compatible with previous studies,31,34 estimates
were scaled to a 20-nmol/L change in 25(OH)D level;
20 nmol/L is approximately the inter-tertile range (66th
percentile to 33rd percentile) observed in a large European
study.31
Results
Validation of instrument strength
We examined each of the MR assumptions in turn. To sat-
isfy the first MR assumption, our SNPs must be clearly
associated with 25(OH)D concentrations; typically, an F-
statistic > 10 is a commonly used threshold for a strong in-
strument. We specifically chose SNPs from DHCR7,
CYP2R1 and GC, which have been clearly shown to be
associated with 25(OH)D concentrations. In Afzal et al.,31
the SNPs we use are very strongly associated where the F-
statistics for each SNP is >90. For the GC SNP, the associ-
ation of this variant with log-transformed 25(OH)D were
adequate with an F-statistic of 13.38. The SNPs combined
explain about 1.3% of the variance in 25(OH)D concen-
tration. It is important to note that these studies were
among few of the many studies linking these SNPs to
25(OH)D concentrations.24,26,28,29,34 This evidence
Table 1. Distribution of cases based on epithelial ovarian car-
cinoma subtypes
EOC subtypes Number of cases
High-grade serous 4121
Low-grade serous 363
Serous of unknown grade 1344
Mucinous 662
Clear cell 621
Endometroid 1350
Others 1604
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combined suggests that the SNPs we used are valid instru-
ments (i.e. weak instrument bias is not a problem in our
study).
Assessment for pleiotropy
Next we assessed possible pleiotropy. Of the known ovar-
ian cancer risk factors, some have an established genetic
component, with large GWASs conducted. Examining
these GWAS findings, we found no evidence for associ-
ation between the SNPs in DHCR7 and CYP2R1 and
potential confounders such as smoking behaviour
(Supplementary Table 1), hence satisfying the second MR
assumption. We found that neither the lead SNPs nor any
SNPs correlated with them were associated with the pos-
sible confounders after Bonferroni corrections. For the
other ovarian cancer risk factors (OC use, parity), large-
scale GWASs have not been conducted because inherited
genetic factors are unlikely to play a major role. The third
MR assumption can be difficult to test directly although
the vitamin D metabolism pathway is well understood and
there is substantial evidence that DHCR7 and CYP2R1
play roles in determining or modulating 25(OH)D
concentration.24,25,34
Population stratification
MR analyses are unbiased when they reflect the true rela-
tionship between genotype and phenotype (rather than e.g.
artefactual associations from unmodelled population struc-
ture). Our estimated genomic control lambda value
(rescaled to 1000 cases and controls) was k1000¼ 1.005,
implying no major effects of population structure.
Principal component analysis showed that the OCAC cases
and controls were well matched for ancestry
(Supplementary Figures 2 and 3, available as
Supplementary data at IJE online).
Association of SNPs to 25(OH)D concentration
To estimate the association of the chosen SNPs on
25(OH)D concentrations, we used SNP-25(OH)D associ-
ation estimates from both published studies26,31 that were
corrected for seasonal variation. It was shown that the
variant rs7944926 near DHCR7 reduced 25(OH)D con-
centration levels by 2.0 nmol/L per risk allele (A) and the
variant rs12794714 in CYP2R1 reduced 25(OH)D concen-
tration levels by 3.0 nmol/L per risk allele (A). Upon per-
forming conversion of the 25(OH)D estimates from the
natural logarithm scale,26 the variant rs2282679 near GC
was shown to reduce 25(OH)D levels by approximately
2.5 nmol/L per 25(OH)D decreasing allele (C).
MR analysis for all ovarian cancer subtypes
We determined the associations between the 25(OH)D
associated SNPs (rs7944926 and rs12794714) and risk of
ovarian cancer in Table 2. rs12794714 and rs2282679 was
directly genotyped in our dataset, whereas rs7944926 was
well imputed (imputation quality score 0.92). For all epi-
thelial ovarian cancer subtypes combined, the estimated
magnitude of association for a 1.0-nmol/L change in
25(OH)D level was 0.0076 [standard error
(SE)¼ 0.0109] for the MR analysis performed via
rs7944926 in DHCR7. This translates into an odds ratio
(OR) of 1.17 (0.76–1.78) per 20-nmol/L decrease in
25(OH)D levels. Similarly, the magnitude of association
was 0.0137, SE¼ 0.0063 for rs12794714 in CYP2R1,
with corresponding OR of 1.31 (1.03–1.69) per 20-nmol/L
decrease in 25(OH)D and the magnitude of association is –
0.0110, SE¼ 0.0082 with OR of 1.25(0.90–1.71) for
Table 2. Mendelian randomization results: 25(OH)D concentration and ovarian cancer
SNPs EA/NEA 25(OH)D per 25(OH)D
decreasing allele (nmol/L)
All epithelial ovarian
subtype (n¼10 065 cases)
Only high-grade serous epithelial
ovarian subtype (n¼4 121 cases)
bzx rzx R
2 bzy rzy bIVW rIVW bzy rzy bIVW rIVW
rs7944926 A/G –2 0.19 0.40% 0.0153 0.0217 –0.0076 0.0109 0.0418 0.0309 –0.0209 0.0154
rs12794714 A/G –3 0.22 0.60% 0.0412 0.0189 –0.0137 0.0063 0.0772 0.0270 –0.0257 0.0091
rs2282679 C/A –2.5 0.70 0.30% 0.0276 0.0205 –0.0110 0.0082 0.0432 0.0292 –0.0173 0.0117
Combined – – – 1.30% – – –0.0118 0.0045 – – –0.0218 0.0067
EA/NEA refers to the Effect Allele and Non-Effect Allele. bzy denotes the magnitude of association of the SNP-outcome estimate. rzx is the standard error of
the SNP-exposure estimate. bzx denotes the magnitude of association of Z, the SNP instrument on X, the modifiable exposure level (25(OH)D). rzy is the standard
error of bzy. R
2 is the proportion of variance in 25(OH)D explained by the SNP(s). bIVW is the estimate and rIVW its standard deviation. bzy is presented on the
log(OR) scale. bIVW is presented on the log(OR) scale for a single unit (1-nmol/L) change in 25(OH)D—see text for OR scale changes for a 20-unit (nmol/L)
change in 25(OH)D. Note: the bzx estimate for rs2282679 is obtained from Mokry et al. and transformed to natural scale (from natural logarithm) using an inter-
cept at e4 (54.59) nmol/L of 25(OH)D. Standard errors for these estimates were calculated from F-statistics. The variance explained (R2) for rs12794714 and
rs7944926 were obtained directly from Afzal et al., whereas the R2 for rs2822679 was computed from Mokry et al.
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rs2282679 in GC. Since all these SNPs are independent, a
more accurate estimate will be obtained from the com-
bined associations of the three SNPs. The combined
weighted magnitude of association is 0.0118, with a SE
of 0.0045. The resultant OR per 20-nmol/L change in
25(OH)D on all epithelial ovarian cancer subtypes com-
bined is 1.27 (1.06–1.51).
MR analysis for high-grade serous ovarian cancer
Similar associations were observed between SNPs for
25(OH)D concentration and high-grade serous epithelial
ovarian cancer. We obtained a magnitude of association
estimate of 0.0209 (SE¼0.0154) and 0.0257
(SE¼ 0.0091) and 0.0173 (SE¼ 0.0117) for rs7944926,
rs12794714 and rs2282679, respectively. This resulted in
an OR of 1.51 (0.83–2.78) using rs7944926, 1.67 (1.18–
2.38) using rs12794714 and 1.41 (0.89–2.23) per
20-nmol/L decrease in 25(OH)D. Weighting across all SNP
instruments yielded an estimated magnitude of 0.0218
(SE¼ 0.0067). Hence, a 20-nmol/L decrease in 25(OH)D
corresponds to an OR of 1.54 (1.19–2.01) for high-grade
serous ovarian cancer (see Figures 2 and 3).
Discussion
Even though the SNPs chosen in our study only explain a
small fraction (1.3%) of the variance of 25(OH)D con-
centration, because our case–control sample was so large,
we were able to demonstrate associations with ovarian
cancer risk. A genetically scored decrease of 20 nmol/L of
serum 25(OH)D concentration levels increased the risk of
epithelial ovarian cancer by about 30% in European-
ancestry women, with a larger association seen in high-
grade serous disease.
Comparison with previous findings
A recent Danish study31 used MR to show that low circu-
lating 25(OH)D concentrations were associated with can-
cer mortality among Europeans. That study did not
separate the associations of risk and mortality and was
underpowered to draw conclusions on any specific cancer
type. Here, for the first time, we demonstrate that, for epi-
thelial ovarian cancer, there is a causal effect of low
25(OH)D concentrations on risk.
Our results are inconsistent with some previous studies
that have reported no associations between 25(OH)D and
ovarian cancer status. The recent meta-analysis8 of 10 indi-
vidual cohort studies (884 cases and 1605 controls) found
no association between 25(OH)D concentration and devel-
opment of ovarian cancer. Findings from epidemiologic
studies may differ from our MR-based results because ob-
servational studies can be affected by confounding and re-
verse causation, though cohort studies such as Yin et al.8
would be expected to be less affected.
Strength and limitations
A strength of our study is that the mechanism through
which our chosen SNPs influence 25(OH)D levels is well
understood. DHCR7 encodes the enzyme 7-dehydrocho-
lestrol reductase, which is responsible for the conversion of
7-dehydrocholestrol to cholesterol. Reduced activities of 7-
dehydrocholestrol reductase, leading to low cholesterol
and accumulation of 7-dehydrocholestrol, are partially at-
tributable to DHCR7 variants.24,25,29 Although rs7944926
lies outside DHCR7, this variant modulates expression of
DHCR7.35 CYP2R1 is an enzyme which converts vitamin
D3 to 25(OH)D in the liver,
36 with rs12794714 unambigu-
ously associated with 25(OH)D concentrations via
GWAS.29 The GC gene has a primary role in vitamin D
transport. Previous studies shown that the rs2282679 vari-
ant in particular were also strongly associated
(P¼ 4.0 1042) with serum vitamin D binding protein
(DBP) based on the study performed on 1674 individuals
in the Twins UK cohort.29 The GC variants were also
hypothesized to affect bioavailability of vitamin D through
variation in circulating DBP. In view of evidence for its as-
sociation towards vitamin D, the rs2282679 SNP is among
one of the most associated variants with 25(OH)D
(P¼ 1.9 10–109) in the SUNLIGHT GWAS.29 These vari-
ants (rs7944926, rs12794714 and rs2282679) thus affect
25(OH)D levels through varying vitamin D metabolism,
bioavailability or transport, rendering them appropriate in-
strumental variables for use in MR.26,27,31,34
One limitation is that our two-sample MR analysis as-
sumes that the standard error of the exposure [SNP to
25(OH)D] estimates is negligibly small.33,37—given the
large sample size in the Danish study,31 this is a reasonable
assumption. In addition, the MR framework assumes a lin-
ear relationship in the association of the SNP instruments
on the underlying exposure. Although our MR estimates
indicate that a decrease of 20 nmol/L in 25(OH)D concen-
tration is associated with a 30% increased risk of epithelial
ovarian cancer, this estimated effect size is derived from a
larger sample size of women with a range of 25(OH)D
concentrations. Previous studies using MR to examine
25(OH)D concentrations with different outcomes have
dealt with this in various ways. For example, the published
study that we used31 assumed linearity of change across
raw 25(OH)D values. In contrast, the study by Mokry
et al.26 on vitamin D and multiple sclerosis (MS)
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considered the association to be linear on log-transformed
25(OH)D.
We examined the implications of these approaches by
re-computing our findings based on exposure estimates on
the original scale (from the Danish study31) and on the log
scale (from MR study on MS26) (see Supplementary Table
2, available as Supplementary data at IJE online). We note
that, in addition to the scale differences, the estimates of
Causal OR for 20nmol/Liter change in 25(OH)D towards 
           risk of ovarian cancer by subtypes
Subtypes
Mucinous
Clear cell
Endometrioid
Serous
Others
All cases
Cases
662
621
1 350
5 828
1 604
10 065
OR (95% CI.)
1.00(0.70, 1.43)
1.27(0.72, 2.24)
1.20(0.81, 1.78)
1.21(0.84, 1.76)
1.10(0.76, 1.60)
1.27(1.06, 1.51)
0.6 1 1.4 1.8 2.2
Odds Ratio
Figure 3. Causal OR of 25(OH)D on individual ovarian cancer subtypes.
Causal OR for 20nmol/Liter change in 25(OH)D on risk of
all ovarian cancer and high grade serous subtype
All subtypes
(N=10 065)
rs12794714
rs7944926
rs2282679
Combined
HG serous
(N=4 121)
rs12794714
rs7944926
rs2282679
Combined
EA/NEA
A/G
A/G
C/A
EA/NEA
A/G
A/G
C/A
OR (95% CI.)
1.31(1.03,1.69)
1.17(0.76,1.78)
1.25(0.90,1.71)
1.27(1.06,1.51)
OR (95% CI.)
1.67(1.18,2.38)
1.51(0.83,2.78)
1.41(0.89,2.23)
1.54(1.19,2.01)
0.6 1 1.4 1.8 2.2
Odds Ratio
Figure 2. Causal OR of 25(OH)D on all ovarian cancer and high grade serous ovarian cancer.
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the magnitude of association of each SNP on 25(OH)D dif-
fered due to random sampling error (with estimates from
the Danish study31 derived from a much larger sample size
than those in the MS study26). We hence repeated our ana-
lysis by adopting SNP-exposure estimates used by the MS
study26 for the SNP rs12785878 (LD to rs7944926 with
r2¼ 1.0) in the DHCR7 gene. Although our result was ro-
bust to differences in scaling [log-transformed or non-
transformed 25(OH)D concentrations, see Supplementary
Table 2, available as Supplementary data at IJE online], in
practice, a 20-nmol/L increase is more likely to make an
impact on women with low 25(OH)D concentrations than
those whose concentration is already high.
In our main analysis, there were concerns that the effect
of the GC SNP on 25(OH)D was not estimated with high
accuracy (GC SNP estimates were based on 2347 individ-
uals26 whereas the estimates for DHCR7 and CYP2R1
were derived based on 30 792 individuals31), as well as
concerns that the GC SNP may not influence 25-hydroxy-
vitamin D’s biological activity in a predictable way.31,38,39
Nonetheless, we conducted a sensitivity analyses to exam-
ine the effect of excluding this SNP. When the GC SNP
was excluded, our results were unchanged (the association
with ovarian cancer of the combined effect of the three
SNPs was very similar to that obtained using just two
SNPs; see Supplementary Table 5, available as
Supplementary data at IJE online).
Another potential limitation of our analysis is residual
pleiotropy. We found no evidence for SNP–confounder as-
sociation based on the subset of participants with available
confounder information (Supplementary Table 6, available
as Supplementary data at IJE online), although we cannot
rule out associations with unmeasured confounders. An
approach such as Egger regression40 can potentially be
applied to further test the MR assumptions but these re-
quire more SNPs than the three employed here.
Interpretation of findings
Observation of a larger magnitude of association
(OR¼ 1.54) with high-grade serous cancer for lower
25(OH)D concentration suggests that the association of
circulating 25(OH)D with risk of ovarian cancer may be
confined to the high-grade serous type, although the confi-
dence limits of the two ORs are overlapping and high-
grade serous cancer is contained within all ovarian cancer.
The results for histological subtypes other than high-grade
serous carcinoma are shown in Figure 3 (for association of
each individual SNP, see Supplementary Table 3, available
as Supplementary data at IJE online) and there is no evi-
dence for association for non-serous disease. For all non-
high-grade serous cancers combined, the OR was 1.12 (0.
89–1.41).
The association of lower circulating vitamin D
[25(OH)D] levels to risk of epithelial ovarian cancer ap-
pear to be consistent with a recent MR study31 looking at
all-cancer mortality. Vitamin D activating enzymes and
vitamin D receptors are present in many tissues, with the
regulation of 1–3% of gene expression in these tissues at-
tributable to vitamin D.35 Studies have also shown that
vitamin D is involved in the regulation of cell processes
(proliferation, differentiation and apoptosis) in several cell
types that are central to the development of cancer.14,41–43
Thus, our findings warrant further investigations on the
biological role of vitamin D [specifically 25(OH)D] in
mortality as well as risk of ovarian cancer.
In conclusion, we demonstrate an association between
low 25(OH)D concentration and risk of ovarian cancer in
women of European ancestry, with our MR approach pro-
viding estimates which are unaffected by the confounding
or biases present in observational studies. Whilst our re-
sults cannot guarantee causality, placed in the context of
other epidemiological studies, they provide additional evi-
dence supportive of a causal link between vitamin D and
risk of ovarian cancer.
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Supplementary Data are available at IJE online.
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